Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

被引：48

作者：

Sharma, Padmanee

Pachynski, Russell Kent

Narayan, Vivek

Flechon, Aude

Gravis, Gwenaelle

Galsky, Matt D.

Mahammedi, Hakim

Patnaik, Akash

Subudhi, Sumit Kumar

Ciprotti, Marika

Duan, Tao

Saci, Abdel

Hu, Sarah

Han, G. Celine

Fizazi, Karim

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[4] Ctr Leon Berard, Lyon, France

[5] Inst Paoli Calmettes, Med Oncol, Marseille, France

[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[7] Ctr Jean Perrin, Clermont Ferrand, France

[8] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

[9] Bristol Myers Squibb, Princeton, NJ USA

[10] Gustave Roussy, Villejuif, France

来源：

关键词：

D O I：

10.1200/JCO.2019.37.7_suppl.142

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

142

引用

页数：2